Soluble PD-L1 Expression After Intravenous Treatment of Cancer Patients With Selenite in Phase I Clinical Trial

por Razaghi, Ali, Mansouri, Ladan, Brodin, Ola, Björnstedt, Mikael, Lundahl, Joachim
Publicado 2022

The role of circulating anti-p53 antibodies in patients with advanced non-small cell lung cancer and their correlation to clinical parameters and survival

por Bergqvist, Michael, Brattström, Daniel, Larsson, Anders, Hesselius, Patrik, Brodin, Ola, Wagenius, Gunnar
Publicado 2004

Intravenous Infusion of High Dose Selenite in End-Stage Cancer Patients: Analysis of Systemic Exposure to Selenite and Seleno-Metabolites

por Breuer, Olof, Brodin, Ola, Razaghi, Ali, Brodin, David, Gammelgaard, Bente, Björnstedt, Mikael
Publicado 2023

Selenoprotein P as Biomarker of Selenium Status in Clinical Trials with Therapeutic Dosages of Selenite

por Brodin, Ola, Hackler, Julian, Misra, Sougat, Wendt, Sebastian, Sun, Qian, Laaf, Elena, Stoppe, Christian, Björnstedt, Mikael, Schomburg, Lutz
Publicado 2020

Effects of redox modulation by inhibition of thioredoxin reductase on radiosensitivity and gene expression

por Selenius, Markus, Hedman, Mattias, Brodin, David, Gandin, Valentina, Rigobello, Maria Pia, Flygare, Jenny, Marzano, Christine, Bindoli, Alberto, Brodin, Ola, Björnstedt, Mikael, Fernandes, Aristi P
Publicado 2012

Pharmacokinetics and Toxicity of Sodium Selenite in the Treatment of Patients with Carcinoma in a Phase I Clinical Trial: The SECAR Study

por Brodin, Ola, Eksborg, Staffan, Wallenberg, Marita, Asker-Hagelberg, Charlotte, Larsen, Erik H., Mohlkert, Dag, Lenneby-Helleday, Clara, Jacobsson, Hans, Linder, Stig, Misra, Sougat, Björnstedt, Mikael
Publicado 2015